Table 1 Baseline characteristics of patients with disease relapse (“relapsers”) or stable disease activity (“nonrelapsers”) during 1 year of follow-up
Characteristic | Total (n = 95) | Nonrelapsers (n = 83) | Relapsers (n = 12) | p value |
|---|---|---|---|---|
Age (years) | 57 (50–66) | 57 (50–66) | 57 (48–63.5) | 0.614 |
Female, n (%) | 61 (64.2%) | 53 (63.9%) | 8 (66.7%) | 1.000 |
Disease duration (years) | 15 (9–21) | 15 (9–21) | 14.5 (7.5–24.5) | 0.831 |
Diagnosis, n (%) | 0.215 | |||
Psoriatic arthritis | 51 (53,7%) | 47 (56.6%) | 4 (33.3%) | |
Rheumatoid arthritis | 44 (46.3%) | 36 (43,4%) | 8 (66.7%) | |
Time to csDMARD (months) | 25.6 (5.1–62.2) | 24.4 (5.5–62.2) | 32.6 (5.1–92.3) | 0.911 |
Time to bDMARD (months) | 98.5 (36.9–165.9) | 98.5 (38.8–160.9) | 95.9 (33.6225.9) | 0.823 |
Time-to-remission/LDA (months) | 3.27 (2.13–4.3) | 3.07 (1.9–3.97) | 20.4 (16.8–24.3) | < 0.001 |
Time-in-remission/LDA (months) | 58.7 (26.7–86.6) | 60.1 (27.6–88.0) | 25.0 (9.4–59.3) | 0.027 |
Calprotectin (μg/mL) | 1.66 (0.69–2.68) | 1.44 (0.62–2.34) | 6.01 (5.01–6.44) | < 0.001 |
CRP (mg/dL) | 0.10 (0.04–0.26) | 0.09 (0.03–0.22) | 0.17 (0.04–0.52) | 0.388 |
ESR (mm) | 10 (7–18) | 10 (7–16) | 14.5 (8–21.5) | 0.225 |
Albumin (g/L) | 42 (31–48) | 43 (31–48) | 31 (31–47) | 0.210 |
Biologic treatment, n (%) | 0.843 | |||
Adalimumab | 34 (35.8%) | 30 (36.1%) | 4 (33.3%) | |
Etanercept | 44 (46.3%) | 39 (47.0%) | 5 (41.7%) | |
Infliximab | 17 (17.9%) | 14 (16.9%) | 3 (25.0%) | |
Biological treatment duration (months) | 61.6 (30.8–91.4) | 63.2 (31.8–92.7) | 39.9 (25.1–61.2) | 0.136 |
Reduced dose of biologicsa, n (%) | 45 (47.4%) | 40 (48.2%) | 5 (41.7%) | 0.672 |
Monotherapy, n (%) | 45 (47.4%) | 42 (50.6%) | 3 (25.0%) | 0.127 |
Concomitant steroids, n (%) | 18 (18.9%) | 13 (15.7%) | 5 (41.7%) | 0.047 |
Global TNFi trough serum levels (μg/mL) | 2.20 (1.07–6.26) | 2.70 (1.18–6.83) | 1.14 (0.73–1.52) | 0.001 |
Adalimumab (μg/mL) | 7.04 (2.69–9.40) | 7.19 (5.78–9.88) | 1.28 (0.73–1.59) | 0.009 |
Etanercept (μg/mL) | 1.45 (1.00–2.25) | 1.52 (0.92–2.32) | 1.24 (1.20–1.54) | 0.698 |
Infliximab (μg/mL) | 2.94 (0.86–3.26) | 3.16 (1.92–4.84) | 0 (0–1.05) | 0.023 |
DAS28-ESR | 2.03 (1.68–2.6) | 1.99 (1.67–2.52) | 2.43 (1.89–2.74) | 0.145 |
Remission, n (%) | 72 (75.8%) | 65 (78.3%) | 7 (58.3%) | 0.175 |
Low disease activity, n (%) | 23 (24.2%) | 18 (21.7%) | 5 (41.7%) | 0.127 |
SDAI | 6.03 (2.2–6.26) | 6.02 (2.11–6.22) | 6.18 (4.53–6.96) | 0.087 |
CDAI | 6 (2–6) | 6 (2–6) | 6 (4–6.5) | 0.220 |
Global ultrasound score | 8 (3–13) | 8 (3–13) | 17.5 (9.5–31) | 0.041 |
PD score | 1 (0–2) | 1 (0–2) | 5.5 (2.5–10) | < 0.001 |
SH score | 7 (3–11) | 6 (3–10) | 8.5 (5–12) | 0.210 |
PDUS, n (%) | 50 (52.6%) | 38 (45.8%) | 8 (66.6%) | < 0.001 |
Number of joints with PDUS | 1 (0–2) | 1 (0–2) | 3.5 (2.5–5) | < 0.001 |
UdAS, n (%) | 29 (30.5%) | 17 (20.5%) | 7 (58.3%) | < 0.001 |